Table 1.

In vitro antitumor activity of the newly synthesized compounds 16–34.

Compounds	MDA-MB-231a IC50 (μM)c	LOVOb IC50 (μM)c
16	16.23 ± 0.32	33.97 ± 0.26
17	14.97 ± 0.37	23.98 ± 0.06
18	12.38 ± 0.3	21.46 ± 0.13
19	12.31 ± 0.11	17.53 ± 0.04
20	16.82 ± 0.13	14.80 ± 0.1
21	14.48 ± 0.03	14.21 ± 0.06
22	18.33 ± 0.01	14.14 ± 0.06
23	17.14 ± 0.01	13.39 ± 0.23
24	11.50 ± 0.36	20.39 ± 0.02
25	11.41 ± 0.07	12.00 ± 0.05
26	11.80 ± 0.02	23.62 ± 0.01
27	18.05 ± 0.04	12.80 ± 0.03
28	37.41 ± 0.06	14.20 ± 0.09
29	38.67 ± 0.04	14.00 ± 1.02
30	13.77 ± 0.4	14.12 ± 0.06
31	10.38 ± 0.22	9.91 ± 0.12
32	18.35 ± 0.14	16.51 ± 0.15
33	20.21 ± 0.05	14.37 ± 0.46
34	20.06 ± 0.11	15.77 ± 0.16
5-FU	70.28 ± 0.2	15.23 ± 0.09
Erlotinib	22.24 ± 0.22	25.31 ± 0.12

^aAggressive human MDA-MB-231 (representative triple negative breast cancer cells with high metastasis potential).

^bAggressive human LOVO colon cell line (type IV metastasized colon cancer).

^cIC₅₀: concentration of the compound (μM) that produced 50% inhibition of cell growth inhibition after 48 h of treatment.